Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Luisa Giaccone, Barry Storer, Francesca Patriarca, Marcello Rotta, Roberto Sorasio, Bernardino Allione, Fabrizio Carnevale-Schianca, Moreno Festuccia, Lucia Brunello, Paola Omedè, Sara Bringhen, Massimo Aglietta, Alessandro Levis, Nicola Mordini, Andrea Gallamini, Renato Fanin, Massimo Massaia, Antonio Palumbo, Giovannino Ciccone, Rainer StorbTed A. Gooley, Mario Boccadoro, Benedetto Bruno

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival (OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = .02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among patients who reached complete remission in these 2 cohorts, 53% and 19% are in continuous complete remission. Among relapsed patients rescued with "new drugs," median OS from the start of salvage therapy was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study.

Original languageEnglish
Pages (from-to)6721-6727
Number of pages7
JournalBlood
Volume117
Issue number24
DOIs
Publication statusPublished - Jun 16 2011

Fingerprint

Autologous Transplantation
Homologous Transplantation
Autografts
Melphalan
Disease-Free Survival
Allografts
Survival
Salvaging
Siblings
Pharmaceutical Preparations
Salvage Therapy
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Giaccone, L., Storer, B., Patriarca, F., Rotta, M., Sorasio, R., Allione, B., ... Bruno, B. (2011). Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood, 117(24), 6721-6727. https://doi.org/10.1182/blood-2011-03-339945

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. / Giaccone, Luisa; Storer, Barry; Patriarca, Francesca; Rotta, Marcello; Sorasio, Roberto; Allione, Bernardino; Carnevale-Schianca, Fabrizio; Festuccia, Moreno; Brunello, Lucia; Omedè, Paola; Bringhen, Sara; Aglietta, Massimo; Levis, Alessandro; Mordini, Nicola; Gallamini, Andrea; Fanin, Renato; Massaia, Massimo; Palumbo, Antonio; Ciccone, Giovannino; Storb, Rainer; Gooley, Ted A.; Boccadoro, Mario; Bruno, Benedetto.

In: Blood, Vol. 117, No. 24, 16.06.2011, p. 6721-6727.

Research output: Contribution to journalArticle

Giaccone, L, Storer, B, Patriarca, F, Rotta, M, Sorasio, R, Allione, B, Carnevale-Schianca, F, Festuccia, M, Brunello, L, Omedè, P, Bringhen, S, Aglietta, M, Levis, A, Mordini, N, Gallamini, A, Fanin, R, Massaia, M, Palumbo, A, Ciccone, G, Storb, R, Gooley, TA, Boccadoro, M & Bruno, B 2011, 'Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma', Blood, vol. 117, no. 24, pp. 6721-6727. https://doi.org/10.1182/blood-2011-03-339945
Giaccone, Luisa ; Storer, Barry ; Patriarca, Francesca ; Rotta, Marcello ; Sorasio, Roberto ; Allione, Bernardino ; Carnevale-Schianca, Fabrizio ; Festuccia, Moreno ; Brunello, Lucia ; Omedè, Paola ; Bringhen, Sara ; Aglietta, Massimo ; Levis, Alessandro ; Mordini, Nicola ; Gallamini, Andrea ; Fanin, Renato ; Massaia, Massimo ; Palumbo, Antonio ; Ciccone, Giovannino ; Storb, Rainer ; Gooley, Ted A. ; Boccadoro, Mario ; Bruno, Benedetto. / Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. In: Blood. 2011 ; Vol. 117, No. 24. pp. 6721-6727.
@article{c0b4fcd8ff114721abac9440e430fd10,
title = "Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma",
abstract = "Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival (OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = .02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among patients who reached complete remission in these 2 cohorts, 53{\%} and 19{\%} are in continuous complete remission. Among relapsed patients rescued with {"}new drugs,{"} median OS from the start of salvage therapy was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study.",
author = "Luisa Giaccone and Barry Storer and Francesca Patriarca and Marcello Rotta and Roberto Sorasio and Bernardino Allione and Fabrizio Carnevale-Schianca and Moreno Festuccia and Lucia Brunello and Paola Omed{\`e} and Sara Bringhen and Massimo Aglietta and Alessandro Levis and Nicola Mordini and Andrea Gallamini and Renato Fanin and Massimo Massaia and Antonio Palumbo and Giovannino Ciccone and Rainer Storb and Gooley, {Ted A.} and Mario Boccadoro and Benedetto Bruno",
year = "2011",
month = "6",
day = "16",
doi = "10.1182/blood-2011-03-339945",
language = "English",
volume = "117",
pages = "6721--6727",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

AU - Giaccone, Luisa

AU - Storer, Barry

AU - Patriarca, Francesca

AU - Rotta, Marcello

AU - Sorasio, Roberto

AU - Allione, Bernardino

AU - Carnevale-Schianca, Fabrizio

AU - Festuccia, Moreno

AU - Brunello, Lucia

AU - Omedè, Paola

AU - Bringhen, Sara

AU - Aglietta, Massimo

AU - Levis, Alessandro

AU - Mordini, Nicola

AU - Gallamini, Andrea

AU - Fanin, Renato

AU - Massaia, Massimo

AU - Palumbo, Antonio

AU - Ciccone, Giovannino

AU - Storb, Rainer

AU - Gooley, Ted A.

AU - Boccadoro, Mario

AU - Bruno, Benedetto

PY - 2011/6/16

Y1 - 2011/6/16

N2 - Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival (OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = .02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among patients who reached complete remission in these 2 cohorts, 53% and 19% are in continuous complete remission. Among relapsed patients rescued with "new drugs," median OS from the start of salvage therapy was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study.

AB - Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival (OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = .02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among patients who reached complete remission in these 2 cohorts, 53% and 19% are in continuous complete remission. Among relapsed patients rescued with "new drugs," median OS from the start of salvage therapy was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and disease-free advantage over standard autografting in this comparative study.

UR - http://www.scopus.com/inward/record.url?scp=79959243080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959243080&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-03-339945

DO - 10.1182/blood-2011-03-339945

M3 - Article

C2 - 21490341

AN - SCOPUS:79959243080

VL - 117

SP - 6721

EP - 6727

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -